Rhumbline Advisers Has $223,000 Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

Rhumbline Advisers increased its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 10.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,996 shares of the company’s stock after acquiring an additional 5,178 shares during the quarter. Rhumbline Advisers owned 0.08% of MeiraGTx worth $223,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Privium Fund Management B.V. bought a new stake in MeiraGTx during the 1st quarter valued at approximately $728,000. Los Angeles Capital Management LLC acquired a new stake in MeiraGTx during the 1st quarter valued at $706,000. Hobbs Group Advisors LLC bought a new position in MeiraGTx in the 2nd quarter valued at $164,000. Sierra Summit Advisors LLC acquired a new stake in MeiraGTx in the 4th quarter valued at about $252,000. Finally, EntryPoint Capital LLC boosted its position in MeiraGTx by 126,511.5% in the 1st quarter. EntryPoint Capital LLC now owns 32,919 shares of the company’s stock valued at $200,000 after buying an additional 32,893 shares during the last quarter. Institutional investors and hedge funds own 67.48% of the company’s stock.

MeiraGTx Stock Performance

NASDAQ MGTX opened at $4.26 on Friday. MeiraGTx Holdings plc has a 1 year low of $3.49 and a 1 year high of $7.60. The firm has a market capitalization of $273.95 million, a price-to-earnings ratio of -3.64 and a beta of 1.28. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 1.04. The firm’s 50 day simple moving average is $4.31 and its 200 day simple moving average is $4.82.

MeiraGTx (NASDAQ:MGTX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.45). MeiraGTx had a negative return on equity of 152.82% and a negative net margin of 1,146.81%. The company had revenue of $0.28 million for the quarter, compared to analyst estimates of $16.38 million. As a group, research analysts expect that MeiraGTx Holdings plc will post -1.37 earnings per share for the current fiscal year.

Insider Activity at MeiraGTx

In related news, Director Perceptive Advisors Llc acquired 1,250,000 shares of the stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $4.00 per share, for a total transaction of $5,000,000.00. Following the purchase, the director now directly owns 12,531,103 shares of the company’s stock, valued at approximately $50,124,412. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on MGTX shares. Royal Bank of Canada cut their target price on MeiraGTx from $11.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Chardan Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of MeiraGTx in a research report on Wednesday, July 31st.

MeiraGTx Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.